Corvus Pharmaceuticals, Inc. Accumulated Other Comprehensive Income
Corvus Pharmaceuticals, Inc. (CRVS) had Accumulated Other Comprehensive Income of -$1.29 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.29M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.13M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$896.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.06M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-06-30 | -$1.29M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$1.13M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | -$896.00K 10-Q · filed 2026-08-06 | |
| 2025-09-30 | -$1.06M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | -$1.15M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | -$1.25M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | -$1.29M 10-K · filed 2026-03-12 | |
| 2024-09-30 | -$738.00K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$1.35M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | -$1.27M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | -$967.00K 10-K · filed 2025-03-25 | |
| 2023-09-30 | -$1.44M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | -$1.37M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | -$434.00K 10-Q · filed 2023-05-08 | |
| 2022-12-31 | -$563.00K 10-K · filed 2024-03-19 | |
| 2022-09-30 | -$1.19M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $339.00K 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $1.99M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $1.87M 10-K · filed 2023-03-28 | |
| 2021-09-30 | $1.38M 10-Q · filed 2021-11-01 | |
| 2021-06-30 | $1.40M 10-Q · filed 2022-08-08 | $1.39M 10-Q · filed 2021-08-02 |
| 2021-03-31 | $6.00K 10-Q · filed 2021-04-29 | |
| 2020-12-31 | $4.00K 10-K · filed 2022-03-10 | |
| 2020-09-30 | $12.00K 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $53.00K 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $43.00K 10-Q · filed 2020-04-30 | |
| 2019-12-31 | $29.00K 10-K · filed 2021-03-25 | |
| 2019-09-30 | $34.00K 10-Q · filed 2019-10-29 | |
| 2019-06-30 | $39.00K 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $11.00K 10-Q · filed 2019-05-09 | |
| 2018-12-31 | -$34.00K 10-K · filed 2020-03-09 | |
| 2018-09-30 | -$35.00K 10-Q · filed 2018-11-01 | |
| 2018-06-30 | -$20.00K 10-Q · filed 2018-08-02 | |
| 2018-03-31 | -$39.00K 10-Q · filed 2018-05-03 | |
| 2017-12-31 | -$41.00K 10-K · filed 2019-03-07 | |
| 2017-09-30 | -$14.00K 10-Q · filed 2017-11-02 | |
| 2017-06-30 | -$52.00K 10-Q · filed 2017-08-03 | |
| 2017-03-31 | -$62.00K 10-Q · filed 2017-05-04 | |
| 2016-12-31 | -$39.00K 10-K · filed 2018-03-01 | |
| 2016-09-30 | $41.00K 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $78.00K 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $29.00K 10-Q · filed 2016-05-05 | |
| 2015-12-31 | -$45.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |